Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc.…
60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On November 19, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Na
- Exchange
- The Nasdaq Stock Market LLC
- Kind
- deficiency
- Rule
- Nasdaq Listing Rule 5550(a)(2)
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The company faces scheduled delisting and trading suspension unless it appeals by Nov. 27, 2026. It also plans a reverse stock split expected to become effective Dec. 2, 2026 to attempt to regain compliance.
Market read
This is a direct exchange-action event with defined deadlines (appeal by Nov. 27, suspension Dec. 1) and an announced corporate action (reverse split effective Dec. 2) that can materially change trading risk.
What to watch
Traders should monitor whether the reverse split is actually executed on Dec. 2 and whether the Panel grants continued listing, since either outcome can sharply change expected delisting timing.
Background
Nasdaq notified the company it failed the minimum bid price requirement for continued listing on the Nasdaq Capital Market, and because of prior reverse splits it is not eligible for a compliance period.
Ticker impact
60 Degrees Pharmaceuticals disclosed Nasdaq staff determined it failed the $1 bid-price rule and will be delisted unless it appeals by Nov. 27.
Likely downward pressure as traders price in delisting risk, with volatility around the appeal deadline and any Panel decision.
The filing states Nasdaq will schedule delisting and suspend trading Dec. 1 unless an appeal is requested by Nov. 27, and it also confirms a planned reverse split to try to regain compliance.
Market effects
No direct sector read-through beyond heightened scrutiny of micro-cap biotech listing compliance risk.
Limited spillover expected, but it can add to Nasdaq small-cap stress sentiment.
Primarily US listing mechanics, with minimal global relevance.
Counterpoint
The reverse split and requested Hearings Panel stay could reduce immediate delisting probability, so the stock may trade as an event-driven rebound rather than a straight fade.
Key entities
- issuer60 Degrees Pharmaceuticals, Inc.
Nasdaq-listed company receiving the delisting notice and planning a reverse stock split.
- exchangeNasdaq Stock Market LLC
Exchange staff issued the delisting determination under the bid price rule.
- regulatorNasdaq Listing Qualifications Department
Staff that determined the company is not in compliance and will be delisted.
- adjudicatorNasdaq Hearings Panel
Panel that can stay suspension pending decision if an appeal is requested.
